Navigation Links
Vessel in Medical Technology

vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque

... Reduced Stenosis, Healthy Endothelial Regrowth in vessel Treated Proactively for Vulnerable Plaque ... mm vProtect(TM) Luminal Shield was placed in the vessel (reference vessel diameter 2.74 mm), resulting in a post-procedural ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

... cell that controls tumor cell division and blood vessel growth - Phase III trials underway to ... cell that controls tumor cell division and blood vessel growth. Preclinical and clinical data have ... a central regulator of tumor cell division, blood vessel growth and cell metabolism. Afinitor is also ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... designed to improve deliverability and vessel support. The first patient was enrolled into the ... disease, and that at two years, the treated vessel was able to expand and contract, without being ... to restore blood flow by propping a clogged vessel open, and to provide support until the ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... bioabsorbable drug eluting stent leaves behind a vessel that expands and contracts in a manner similar to a vessel that has never been stented, which could be an ... device has the potential to provide optimal vessel scaffolding and drug delivery capability over the ...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

... from the global, multi-center TAXUS ATLAS Small vessel (SV) and Long Lesion (LL) studies, designed to ... They reported a significant reduction in small vessel in-stent restenosis and major adverse coronary ... "We are pleased to have a second-generation small vessel DES and the U.S. market's first long DES under ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... a 32 percent reduction in the risk of target vessel failure (TVF, cardiac events related to the ... outcomes defined as cardiac death, MI or target vessel revascularization (TVR). -- A 40 percent ... Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. ...

Exercise Helps Prevent Age-Related Brain Changes in Older Adults

... cognitive decline in the elderly. The blood vessel and flow differences may be one reason." ... for shape and size. They then compared the blood vessel characteristics and how they related to blood ... a novel 3-D computer modeling system to analyze vessel characteristics. Note: Copies of RSNA ...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

... superiority to TAXUS in the endpoints of target vessel failure (TVF) and major adverse cardiac events ... reduction in the risk of ischemia-driven Target vessel Failure (TVF, cardiac events related to ... attack (myocardial infarction or MI) or target vessel revascularization (TVR). -- A clinically ...

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

... the TAXUS ATLAS Workhorse, Direct Stenting, Small vessel and Long Lesion trials were presented at the ... was reported at nine months, the overall target vessel revascularization (TVR) rate through three years ... said Dr. Turco. TAXUS Atlas Small vessel and Long Lesion Two-year data from the TAXUS ...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

... -- TAXUS ATLAS Workhorse, Direct Stenting, Small vessel and Long Lesion studies. Three-year data from the ... two-year data from the TAXUS ATLAS Small vessel and Long Lesion studies will be presented by John ... Vessels and Long Lesions in the TAXUS ATLAS SMALL vessel and TAXUS ATLAS LONG LESION Trials". TAXUS ATLAS ...

September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging

... vision. Severe Headache Could Signal Blood vessel Inflammation ROCHESTER, Minn. -- Severe and ... It also may include a biopsy of an affected blood vessel or tissue. Treatment depends on the type of ... applications under development are mapping blood vessel flow within organs and visualizing clogged ...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008

... to complex patients with left main and three vessel disease treated with drug- eluting stents (DES)," ... to CABG in patients with left main and/or three vessel disease. The presentation will be part of an ... in patients with left main or three vessel disease. In the U.S., the TAXUS Liberte Stent is ...

Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes

... impact on diabetes-related blood vessel dysfunction MCLEAN, Va., May 27 /PRNewswire/ -- ... have the potential to positively impact the blood vessel dysfunction associated with diabetes, suggests a ... experienced a 30 percent improvement in measured vessel function at the completion of a 30-day trial. ...

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

... that controls tumor cell division and blood vessel growth - RAD001 is currently being studied in ... of tumor cell division and blood vessel growth in cancer cells. "This is the first ... tumor cell division, cell metabolism, and blood vessel growth. RAD001 is a once-daily oral therapy that ...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

... by clinically significant reductions in target vessel failure and MACE, XIENCE V demonstrated an even ... -- A 32 percent reduction in the risk of Target vessel Failure (TVF, cardiac events related to the ... (myocardial infarction or MI) or target vessel revascularization (TVR). -- A 40 percent ...

Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery

... randomized pivotal clinical trial comparing graft vessel connections made using the PAS-Port system to ... to consistently and reliably attach a graft vessel to the aorta, generally in about two minutes," ... with little or no injury to the bypass graft vessel or the aorta. Importantly, the PAS-Port ...

Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent

... In-Segment Late Loss, Non-Inferiority in Target vessel Failure and Low Rates of MACE with XIENCE ... resulted in a significant 50 percent reduction in vessel renarrowing (in-segment late loss) at eight months, non-inferior rates of target vessel failure (TVF) at nine months, and an observed 42 ...

In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy

... restenosis, the hazardous narrowing of a blood vessel that often occurs despite the presence of a stent ... time the coating releases drugs meant to reduce vessel injury. Bare metal stents produce ... is released within 12 to 24 hours, after which vessel blockages regrow," said Levy. "In this study, the ...

VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation

... drug that targets inflammation in the blood vessel wall, a primary disease process in ... as well as medical imaging of the coronary vessel wall to evaluate impact on ... medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of ...

VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis

... and the buildup of plaque in arterial blood vessel walls. Research in both humans and mice has noted ... drug that targets inflammation in the blood vessel wall, a primary disease process ... oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of ...

VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome

... VIA-2291 targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis and ... drug that targets inflammation in the blood vessel wall, a primary disease process ... oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of ...

Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

... to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a ... offers a comprehensive portfolio of vessel closure, endovascular and coronary products that ...

Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions

... data from the pivotal TAXUS ATLAS Small vessel and Long Lesion studies, which evaluate the ... the U.S. in 2008." The TAXUS ATLAS Small vessel and Long Lesion studies are global, ... lesions in 411 patients at 24 sites. The Small vessel study was designed to evaluate the safety and ...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

... and continued non- inferior rates of target vessel failure (TVF) with XIENCE V compared to the ... to TAXUS. (In-segment late loss is a measure of vessel renarrowing). The SPIRIT III clinical trial of ... -- In the major secondary endpoint of Target vessel Failure (TVF), XIENCE V continued to ...

Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis

... evaluate whether renal artery stenting may reduce vessel renarrowing, thereby potentially reducing other ... is binary restenosis at nine months, a measure of vessel renarrowing. Secondary endpoints in the trial ... a measure of the need to retreat a diseased vessel that has renarrowed. About the Investigational ...

Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results

... cardiac events (MACEs) reported that may possibly be related to target vessel revascularization, four (33%) may have been related to the PAS-Port system ... in approximately two minutes, with little or no injury to the bypass graft vessel or the aorta. As of March 31, 2009, almost 14,000 PAS-Port systems had ...

Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients

... and services of Guidant Cardiac Surgery and the VASOVIEW endoscopic vessel harvesting system. The creation of this new organization enables MAQUET ... comprehensive array of patient care solutions for less-invasive endoscopic vessel harvesting, off- and on-pump coronary artery bypass surgery and vascular ...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

... The EPIC Stent is a self-expanding nitinol stent designed to sustain vessel patency (openness), while providing enhanced visibility during placement. ... (MI, or heart attack) occurring during related hospitalization, target vessel revascularization (TVR) through nine months and amputation of the treated ...

Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data

... treatment of stenotic or occluded vessels, doctors widen the narrowed vessel using an angioplasty balloon catheter. In some cases, a stent, which is a metal scaffold, is then placed to hold the vessel open. However, these treatments may have limited effectiveness since, for ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... mm for XIENCE V vs. 0.36 mm for TAXUS). In-stent late loss is a measure of vessel re-narrowing. About XIENCE V XIENCE V is used to treat coronary ... Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. About Abbott Abbott ...

Chemoembolization Improving as Liver Cancer Treatment

... size of the beads themselves so that they can more fully block the blood vessel and further guard against potential leakage of blood that could feed the ... Hospital and Medical Center. "The more isolated the tumor and its blood vessel feeders, the better the chance for a complete cure." Improvements in ...

OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications

... and resulting products to market based on the idea that controlling blood vessel growth would improve human body management for a diverse set of medical ... level -- accelerating cellular-cased biologic therapies to control blood vessel growth. These nano-materials will enable doctors to treat disease at ...

Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent

... at nine months. A second parallel study named the TAXUS PERSEUS Small vessel study will compare the TAXUS Element Stent to a historic control (TAXUS V ... from 2.25 up to 2.75 millimeters. The primary endpoint of the small vessel study is in-stent late loss at nine months, and its secondary endpoint is ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... for this debilitating, rapidly progressive and incurable blood vessel disease -- Imatinib mesylate, available as Gleevec(R) for treatment of ... of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II ...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial

... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed ... a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its ...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

... the mTOR protein, a central regulator of cell division and tumor blood vessel growth. Data suggest RAD001 has clinical activity as a single agent or in ... as a central regulator of tumor cell division, cell metabolism and blood vessel growth. If approved, RAD001 will become the first oral, once-daily therapy ...

Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study

... Pre-Clinical Data Shows Increased Muscle and Blood vessel Formation in Animals' Hearts SUNRISE, Fla., ... that myoblasts expressing SDF-1 resulted in increased muscle and blood vessel formation in the damaged areas of the hearts, which was not observed in ...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial

... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed ... a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its ...

Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms

... wide openings, called "necks." Aneurysms form when a weakness in a blood vessel wall causes the vessel to balloon out and form a thin-walled, blood-filled pouch. If this pouch, or sac, develops in a brain blood vessel and bursts, a patient can sustain a devastating, even lethal, stroke as ...

Cardica to Host Investor Briefing on 'Revolutionizing Revascularization'

... which are designed to allow surgeons to automate the attachment of blood vessel grafts during CABG procedures, replacing traditional hand-sewn sutures. ... in Atlanta. As previously announced, the trial, which compared graft vessel connections made using the PAS-Port system to conventional hand-sewn ...
Other Contents
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
Other TagsOther Tags